Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03287271 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT03287271 · ClinicalTrials.gov record · last posted 2026-07-31

ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK

StatusTerminated
PhasePhase 1/2
Started2018-02-06
View on ClinicalTrials.gov ↗
Why the trial stopped
Due to loss of funding
from the ClinicalTrials.gov record
The purpose of the study is to investigate the combination VS-6063, carboplatin, and paclitaxel. in the treatment of patients with ovarian cancer.

Protocol amendment history 7 changes detected by DataLookout

2026-08-01
Trial terminated
2026-08-01
Trial terminated: Due to loss of funding
2026-08-01
Primary endpoint(s) modified
WasObjective response rate (ORR), To assess the safety and tolerability of VS-6063 plus paclitaxel and carboplatin chemotherapy (Measured Via Adverse Events)
NowDose-Limiting Toxicity, Objective Response Rate (ORR)
2026-08-01
Enrollment reduced: 90 → 8 participants
2026-08-01
Trial arms changed: 1 → 2
2026-08-01
Primary completion moved earlier: 2025-04 → 2023-07-30
2026-08-01
Completion moved earlier: 2026-04 → 2025-03-12
Trial Details
NCT Number NCT03287271
Lead Sponsor Michael McHale
Collaborators: Verastem, Inc., Nine Girls Ask
Conditions Ovarian Cancer
Enrollment 8 participants
Start Date 2018-02-06
Primary Completion 2023-07-30 (estimated)
Study Completion 2025-03-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-31